Trial Outcomes & Findings for Effect of Ketorolac on Post Adenotonsillectomy Pain (NCT NCT03467750)
NCT ID: NCT03467750
Last Updated: 2024-09-19
Results Overview
The total postoperative morphine dosage required to achieve analgesia (defined as a Face, Legs, Activity, Cry, Consolability (FLACC) Scale score of less than 3) in children with obstructive sleep apnea undergoing adenotonsillectomy was compared between study arms to examine the effect of ketorolac administration.
COMPLETED
PHASE4
63 participants
Until PACU discharge (up to 261 minutes)
2024-09-19
Participant Flow
Participants were recruited from Children's Healthcare of Atlanta at Egleston in Atlanta, Georgia, USA. Participant enrollment began July 19, 2018 and the final study assessment occurred on August 22, 2023.
Participant milestones
| Measure |
Ketorolac
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
Ketorolac: Patients in this group received 0.5mg/kg of ketorolac, administered intravenously.
Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given.
A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.
The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered.
|
Standard of Care
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given.
A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.
The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered.
|
|---|---|---|
|
Overall Study
STARTED
|
30
|
33
|
|
Overall Study
COMPLETED
|
28
|
31
|
|
Overall Study
NOT COMPLETED
|
2
|
2
|
Reasons for withdrawal
| Measure |
Ketorolac
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
Ketorolac: Patients in this group received 0.5mg/kg of ketorolac, administered intravenously.
Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given.
A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.
The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered.
|
Standard of Care
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
Standard of Care: All patients underwent inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl were administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen were administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron were given.
A rescue dose of 0.5-1mcg/kg of IV Fentanyl was available for use at the end of the procedure. The decision to administer was left to the discretion of the attending anesthesiologist. The choice to give this was made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.
The PACU nurses, who were blinded to ketorolac administration, evaluated the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg was administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg was administered.
|
|---|---|---|
|
Overall Study
Surgery canceled
|
1
|
0
|
|
Overall Study
Protocol Violation
|
1
|
1
|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
Baseline Characteristics
Effect of Ketorolac on Post Adenotonsillectomy Pain
Baseline characteristics by cohort
| Measure |
Ketorolac
n=30 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=33 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
Total
n=63 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
4.43 years
STANDARD_DEVIATION 3.20 • n=5 Participants
|
4.36 years
STANDARD_DEVIATION 2.91 • n=7 Participants
|
4.40 years
STANDARD_DEVIATION 3.03 • n=5 Participants
|
|
Sex: Female, Male
Female
|
11 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
30 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
19 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
33 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
14 Participants
n=5 Participants
|
20 Participants
n=7 Participants
|
34 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
16 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
26 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
30 participants
n=5 Participants
|
33 participants
n=7 Participants
|
63 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Until PACU discharge (up to 261 minutes)Population: This analysis includes participants who completed the study.
The total postoperative morphine dosage required to achieve analgesia (defined as a Face, Legs, Activity, Cry, Consolability (FLACC) Scale score of less than 3) in children with obstructive sleep apnea undergoing adenotonsillectomy was compared between study arms to examine the effect of ketorolac administration.
Outcome measures
| Measure |
Ketorolac
n=28 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=31 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Post-Anesthesia Care Unit (PACU) Morphine Requirements
|
0.033 mg/kg
Standard Deviation 0.034
|
0.058 mg/kg
Standard Deviation 0.096
|
SECONDARY outcome
Timeframe: 10 minutes post-op, 20 minutes post-op, PACU discharge (up to 261 minutes)Population: This analysis includes participants who completed the study.
Post-Anesthesia Care Unit (PACU) nurses evaluated the patients using Face, Legs, Activity, Cry, Consolability (FLACC) Scale scores at 10 minutes post-op, 20 minutes post-op and at time of PACU discharge. Each category is scored as 0 (no indication of pain), 1 (indication of moderate pain), or 2 (visibly experiencing severe pain). Total scores range from 0 to 10, with higher scores indicating more pain.
Outcome measures
| Measure |
Ketorolac
n=28 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=31 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score
10 minutes post-op
|
1.74 score on a scale
Standard Deviation 2.80
|
2.87 score on a scale
Standard Deviation 3.86
|
|
Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score
20 minutes post-op
|
2.37 score on a scale
Standard Deviation 3.13
|
3.23 score on a scale
Standard Deviation 3.67
|
|
Face, Legs, Activity, Cry, Consolability (FLACC) Scale Score
PACU discharge
|
0.85 score on a scale
Standard Deviation 1.13
|
0.77 score on a scale
Standard Deviation 1.15
|
SECONDARY outcome
Timeframe: Until PACU discharge (up to 261 minutes)Population: This analysis includes participants who completed the study.
The duration of time that a participant was in the Post-Anesthesia Care Unit (PACU), following surgery, measured in minutes.
Outcome measures
| Measure |
Ketorolac
n=28 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=31 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Post-Anesthesia Care Unit (PACU) Recovery Time
|
63.4 minutes
Standard Deviation 39.9
|
49.7 minutes
Standard Deviation 12.2
|
SECONDARY outcome
Timeframe: Up to 14 days after surgeryPopulation: This analysis includes participants who completed the study.
Participants were monitored via medical chart review for post-tonsillectomy bleeding.
Outcome measures
| Measure |
Ketorolac
n=28 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=31 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Number of Participants With Post-Tonsillectomy Bleeding
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Surgery through hospital discharge (up to post-operative day 2)Population: This analysis includes participants who completed the study.
The total amount of pain medications administered during hospitalization was examined.
Outcome measures
| Measure |
Ketorolac
n=28 Participants
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=31 Participants
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Pain Medication Administration
|
0.017 Morphine Equivalents in mg/kg
Standard Error 0.04
|
0.040 Morphine Equivalents in mg/kg
Standard Error 0.093
|
Adverse Events
Ketorolac
Standard of Care
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Ketorolac
n=29 participants at risk
Participants randomized to the ketorolac group received 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis was achieved.
|
Standard of Care
n=32 participants at risk
Participants randomized to this group received the pain management standard of care for the adenotonsillectomy procedure.
|
|---|---|---|
|
Injury, poisoning and procedural complications
Post-operative bleeding requiring surgery
|
3.4%
1/29 • Number of events 1 • Information on adverse events was collected among participants who completed the surgery, beginning at the time of consent and continued through the final assessment at complete recovery, up to 14 days after surgery.
Post-tonsillectomy bleeding requiring surgery is a known risk of tonsillectomy and is not considered to be a serious adverse event in this study.
|
6.2%
2/32 • Number of events 2 • Information on adverse events was collected among participants who completed the surgery, beginning at the time of consent and continued through the final assessment at complete recovery, up to 14 days after surgery.
Post-tonsillectomy bleeding requiring surgery is a known risk of tonsillectomy and is not considered to be a serious adverse event in this study.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place